The Clinical Protocol and Data Management arm of UCLA's Jonsson Comprehensive Cancer Center (JCCC) is administered by the JCCC Clinical Research Unit (CRU). The CRU was established in 1993 as the first major facility for support of clinical cancer research at UCLA. The establishment of this unit was critical to move the Division of Clinical/Transitional Research of the JCCC and its investigators into a position from which it could play a significant role in investigator-initiated, cooperative group and industry-sponsored clinical research in cancer. Data Safety and Monitoring is also contained in this section of our proposal and is overseen by the JCCC Office of Regulatory Compliance (ORC). The ORC is a separate entity within the JCCC that manages our protocol review and monitoring activities and is responsible for reporting to CTRP and clinicaltrials.gov.
Clinical research requires a wide variety of services to support faculty in the conduct of clinical trials. The JCCC Clinical Research Unit facilitates many of these activities. Data Safety and Monitoring supports our clinical trials activities by ensuring that trials are conducted in a safe and regulatory-compliant manner.
|Li, Gang; Lu, Xuyang (2015) A Bayesian approach for instrumental variable analysis with censored time-to-event outcome. Stat Med 34:664-84|
|Epeldegui, Marta; Blom, Bianca; Uittenbogaart, Christel H (2015) BST2/Tetherin is constitutively expressed on human thymocytes with the phenotype and function of Treg cells. Eur J Immunol 45:728-37|
|Bower, Julienne E; Crosswell, Alexandra D; Stanton, Annette L et al. (2015) Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial. Cancer 121:1231-40|
|Arensman, Michael D; Telesca, Donatello; Lay, Anna R et al. (2014) The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther 13:2303-14|
|Li, Keyu; Tavaré, Richard; Zettlitz, Kirstin A et al. (2014) Anti-MET immunoPET for non-small cell lung cancer using novel fully human antibody fragments. Mol Cancer Ther 13:2607-17|
|Ke, Ruian; Loverdo, Claude; Qi, Hangfei et al. (2014) Modelling clinical data shows active tissue concentration of daclatasvir is 10-fold lower than its plasma concentration. J Antimicrob Chemother 69:724-7|
|Fu, Maoyong; Maresh, Erin L; Helguera, Gustavo F et al. (2014) Rationale and preclinical efficacy of a novel anti-EMP2 antibody for the treatment of invasive breast cancer. Mol Cancer Ther 13:902-15|
|Leoh, Lai Sum; Morizono, Kouki; Kershaw, Kathleen M et al. (2014) Gene delivery in malignant B cells using the combination of lentiviruses conjugated to anti-transferrin receptor antibodies and an immunoglobulin promoter. J Gene Med 16:11-27|
|Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206|
|De Azambuja, Katherine; Barman, Provabati; Toyama, Joy et al. (2014) Validation of an HPV16-mediated carcinogenesis mouse model. In Vivo 28:761-7|
Showing the most recent 10 out of 192 publications